Exicure (Exicure) Short-Term Capital Lease Obligation : $0.58 Mil (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Exicure Short-Term Capital Lease Obligation?

Exicure's Short-Term Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.58 Mil.

Exicure's quarterly Short-Term Capital Lease Obligation increased from Dec. 2022 ($0.54 Mil) to Mar. 2023 ($0.56 Mil) and increased from Mar. 2023 ($0.56 Mil) to Jun. 2023 ($0.58 Mil).

Exicure's annual Short-Term Capital Lease Obligation increased from Dec. 2020 ($0.22 Mil) to Dec. 2021 ($0.46 Mil) and increased from Dec. 2021 ($0.46 Mil) to Dec. 2022 ($0.54 Mil).

Exicure Short-Term Capital Lease Obligation Historical Data

The historical data trend for Exicure's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exicure Short-Term Capital Lease Obligation Chart

Exicure Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.29

0.22

0.46

0.54

Exicure Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.50	0.52	0.54	0.56	0.58

Exicure Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Exicure Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Exicure's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Exicure (Exicure) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exicure Inc (NAS:XCUR) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

2H0A:Germany 2H0A:Germany

Address

2430 N. Halsted Street, Suite 410, Chicago, IL, USA, 60614

Website

https://www.exicuretx.com

Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.

Executives

Minhee Eom	director	2430 N. HALSTED ST., CHICAGO IL 60614
Dongho Lee	director	2430 N. HALSTED ST., CHICAGO IL 60614
Hyuk Joon Ko	director	2430 N. HALSTED ST., CHICAGO IL 60614
Hojoon Lee	director	2430 N. HALSTED ST., CHICAGO IL 60614
Dgp Co., Ltd.	10 percent owner	23, GEURINTEKEU-RO, YEONGGWANG-EUP, YEONGGWANG-GUN, JEOLLANAM-DO M5 57024
Jung Sang Kim	director, officer: Chief Executive Officer, CFO	46-31 CHEONGRO 3 GIL, GEUMSUNG-MYEON, UEISUNG-GUN, GYEONGSANGBUK-DO M5 37357
Josh Miller	director, officer: Chief Executive Officer, CFO	2430 N. HALSTED ST., CHICAGO IL 60614
Jiyoung Hwang	director	C/O EXICURE, INC., 2430 N. HALSTED ST., CHICAGO IL 60614
Cheolho Jo	director	2430 N. HALSTED ST., CHICAGO IL 60614
Seung Soo Shin	director	2430 N. HALSTED ST., CHICAGO IL 60614
Hyukku Lee	director	2430 N. HALSTED ST., CHICAGO IL 60614
Sung Uh Kang Paul	director	2430 N. HALSTED ST., CHICAGO IL 60614
Changil Ahn	director	2430 N. HALSTED ST., CHICAGO IL 60614
Cbi Usa, Inc.	10 percent owner	3000 WESTERN AVENUE, SUITE 400, SEATTLE WA 98121
Bali Muralidhar	director	C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077